JonesResearch raised the firm’s price target on Crinetics to $56 from $52 and keeps a Buy rating on the shares. The company’s Phase 3 PATHFNDR-2 data in acromegaly “are an unambiguous win,” the analyst tells investors in a research note. The firm believes the data will establish paltusotine as the “drug of choice” for patients with acromegaly. Crinetics shares still have room to run, says the firm, which increased its probability of success in acromegaly to 95% from 80%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- Crinetics Pharmaceuticals’ Paltusotine Shows Promising Results
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics price target raised to $54 from $48 at Oppenheimer
- Crinetics Pharmaceuticals Advances with Promising Phase 2 Results
- Crinetics reports topline results from paltusotine study
